Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
(NASDAQ:WAVE) Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7....
What are the projected milestones and timeline for FDA approval and commercialization following this trial result?
What does the achieved serum AAT protein level mean relative to existing therapies for Alpha‑1 Antitrypsin deficiency?
How will the positive RestorAATion-2 trial update influence WAVE's near‑term share price and trading volume?
11 days ago